PyroGenesis - CEO, P. Peter Pascali.
CEO, P. Peter Pascali.
Source: PyroGenesis.
  • PyroGenesis Canada (PYR) has completed a non-brokered private placement for gross proceeds of $5,000,000
  • Under the private placement, the company issued 5,000,000 units at a price of $1.00 per unit
  • The company plans to use the net proceeds from the private placement for working capital and general corporate purposes
  • PyroGenesis Canada Inc. is a leader in the design, development, manufacture and commercialization of advanced plasma processes and sustainable solutions which reduce greenhouse gases
  • PyroGenesis Canada Inc. (PYR) opened trading at $1.33 per share

PyroGenesis Canada (PYR) has completed a non-brokered private placement for gross proceeds of $5,000,000.

Under the private placement, the company issued 5,000,000 units at a price of $1.00 per unit.

P. Peter Pascali, the President and CEO of PyroGenesis, subscribed to 2,500,000 units in which Research Capital Corporation acted as financial advisor.

Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of $1.25 until March 7, 2025.

The common shares and warrants issued in connection with the private placement, and the common shares underlying the warrants, are subject to a hold period of four months and one day from the date of closing.

The company plans to use the net proceeds from the private placement for working capital and general corporate purposes.

PyroGenesis Canada Inc., a high-tech company, is a leader in the design, development, manufacture and commercialization of advanced plasma processes and sustainable solutions which reduce greenhouse gases (GHG) and are economically attractive alternatives to conventional “dirty” processes.

PyroGenesis Canada Inc. (PYR) opened trading at $1.33 per share.


More From The Market Online

FSD Pharma submits MS treatment clinical trial for review in Australia

FSD Pharma (CSE:HUGE) submits its MS treatment's Phase-1 Multiple Ascending Doses Clinical Trial Application for ethics review in Australia.

Cloud DX signs fourth contract with a provincial health authority

Cloud DX (TSXV:CDX) signs its fourth contract with a provincial health authority for remote patient monitoring.

International Petroleum stock rallies on Q1 results

Canadian energy stock International Petroleum Corp. (TSX:IPCO) rose in Tuesday trading on its Q1 2024 financial...

York Harbour Metals reveals promising rare earth sampling assays

York Harbour Metals (TSXV:YORK) shares positive assays from its Bottom Brook rare earth elements project in Newfoundland and Labrador.